Trump says Iran war "close to over" amid hopes for more negotiations
Investing.com - Cantor Fitzgerald reiterated an Overweight rating and $245.00 price target on Tenet Healthcare (NYSE:THC).
The firm’s survey suggests year-over-year outpatient surgeries of 2.3%, up from 1.9% in the fourth quarter of 2025. Excluding outliers, the figure stands at 1.9%.
Cantor Fitzgerald views the outpatient trends as relatively in line with consensus expectations. The firm notes the data appears fairly similar to the 30 basis point quarter-over-quarter increase consensus estimates for Tenet Healthcare to 1.9%.
The survey results also align with the blended 2.2% volume consensus for HCA Healthcare, which commands a $111.5 billion market cap and generated $75.6 billion in revenue over the last twelve months. According to InvestingPro Tips, HCA stands as a prominent player in the Healthcare Providers & Services industry, with 6 analysts recently revising earnings upwards for the upcoming period. The comparison includes Surgery Partners at 1.6%.
Cantor Fitzgerald sees volumes as unlikely to surge beyond guidance. For deeper insights into HCA Healthcare’s performance metrics and growth prospects, investors can access comprehensive Pro Research Reports available on InvestingPro, covering this and 1,400+ other US equities.
In other recent news, HCA Healthcare has been a focal point for analysts with several updates on its stock rating and price targets. Cantor Fitzgerald reiterated its Overweight rating on HCA Healthcare, maintaining a price target of $588.00. This decision was supported by HCA’s strong performance in inpatient psychiatric and physician bonuses, as well as positive survey results indicating a favorable outlook for 2026 compared to 2025. Additionally, TD Cowen raised its price target for HCA Healthcare to $561 from $529, while continuing to recommend a Buy rating. This adjustment reflects increased confidence in HCA’s ability to meet its 2026 guidance, following insights shared at the TD Cowen healthcare conference. Meanwhile, Cantor Fitzgerald also reiterated a Neutral rating for Acadia Healthcare, with a price target of $20.00, noting a positive outlook for patient days in 2026. These developments highlight the attention HCA Healthcare is receiving from analysts, with a focus on its financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.